Antibody-drug conjugates in cancer therapy
- PMID: 23043493
- DOI: 10.1146/annurev-med-050311-201823
Antibody-drug conjugates in cancer therapy
Abstract
An antibody-drug conjugate (ADC) provides the possibility of selectively ablating cancer cells by combining the specificity of a monoclonal antibody (mAb) for a target antigen with the delivery of a highly potent cytotoxic agent. ADC target antigens are typically highly expressed on the surface of cancer cells compared to normal cells. The tumor target, the cytotoxic agent, and the manner in which the agent is attached to the antibody are key determinants of clinical activity and tolerability. Recently, several clinical trials have demonstrated that ADCs achieve higher clinical response rates than unconjugated mAbs targeting the same cell surface antigen. Brentuximab vedotin represents one such ADC that has recently been approved for the treatment of relapsed Hodgkin and systemic anaplastic large cell lymphomas--both characterized by high expression of the target antigen, CD30, on the surface of malignant cells. This review summarizes key characteristics of current, clinically active ADCs and highlights recent clinical data illustrating the benefit of antibody-targeted delivery of cytotoxic agents to cancer cells.
Similar articles
-
Antibody-targeted drugs and drug resistance--challenges and solutions.Drug Resist Updat. 2015 Jan;18:36-46. doi: 10.1016/j.drup.2014.11.001. Epub 2014 Nov 21. Drug Resist Updat. 2015. PMID: 25476546 Review.
-
Potent antibody drug conjugates for cancer therapy.Curr Opin Chem Biol. 2009 Jun;13(3):235-44. doi: 10.1016/j.cbpa.2009.03.023. Epub 2009 May 4. Curr Opin Chem Biol. 2009. PMID: 19414278 Review.
-
[Antibody-drug conjugates: a new therapeutic class?].Rev Med Suisse. 2013 May 22;9(387):1080-2, 1084-6. Rev Med Suisse. 2013. PMID: 23757915 French.
-
The next generation of antibody drug conjugates.Semin Oncol. 2014 Oct;41(5):637-52. doi: 10.1053/j.seminoncol.2014.08.001. Epub 2014 Aug 12. Semin Oncol. 2014. PMID: 25440608 Review.
-
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.Nat Prod Rep. 2013 May;30(5):625-39. doi: 10.1039/c3np20113a. Nat Prod Rep. 2013. PMID: 23525375 Review.
Cited by
-
Total Synthesis and Bioactivity Mapping of Geodiamolide H.Chemistry. 2021 Aug 11;27(45):11633-11642. doi: 10.1002/chem.202100989. Epub 2021 Jun 25. Chemistry. 2021. PMID: 34032329 Free PMC article.
-
Mechanisms of action of therapeutic antibodies for cancer.Mol Immunol. 2015 Oct;67(2 Pt A):28-45. doi: 10.1016/j.molimm.2015.04.002. Epub 2015 Apr 23. Mol Immunol. 2015. PMID: 25911943 Free PMC article. Review.
-
Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia.Biomaterials. 2015 Oct;67:42-51. doi: 10.1016/j.biomaterials.2015.07.025. Epub 2015 Jul 15. Biomaterials. 2015. PMID: 26204224 Free PMC article.
-
Understanding the promising role of antibody drug conjugates in breast and ovarian cancer.Heliyon. 2023 Oct 30;9(11):e21425. doi: 10.1016/j.heliyon.2023.e21425. eCollection 2023 Nov. Heliyon. 2023. PMID: 38027672 Free PMC article.
-
Antibody-Drug Conjugates for Cancer Therapy.Molecules. 2020 Oct 16;25(20):4764. doi: 10.3390/molecules25204764. Molecules. 2020. PMID: 33081383 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
